Reports
Sale
Global Anxiety and Depression Treatment Market Share, Size, Trends: By Product: Antidepressant Drugs, Therapy and Devices; By Indication: Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), Phobia, Others; By Distribution Channel: Hospital Pharmacy, Others; Regional Analysis; Supplier Landscape; 2024-2032
Global Anxiety and Depression Treatment Market Outlook
The global anxiety and depression treatment market size was valued at USD 10.05 billion in 2023. The market drivers are developing healthcare market, increasing diagnosis of mental conditions, awareness about the importance of treatments, and the rising inclination towards therapies. The market is projected to grow at a CAGR of 2.6% during the forecast period 2024-2032 to reach a value of USD 12.67 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Therapy and Devices Segment to Propel the Market Growth of Anxiety and Depression Treatment
There is a growing adoption of therapies over anti-depressants due to the absence of side effects such as liver damage, epileptic fits, and heart problems, among others. In addition, the availability of different kinds of therapies such as Cognitive Behavioural Therapy, Dialectical Behavioural Therapy (DBT), and others are leading to the anxiety and depression treatment market growth.
The government initiatives to create awareness regarding psychotherapy and provide these services to the general population for treating anxiety and depression is significantly catalysing the market growth. For instance, the Improving Access to Psychological Therapies (IAPT) by the National Health Service, England aims towards treating anxiety and depression in England by training new therapists and deploying them in the services.
Further, the rising approvals of devices to treat anxiety and depression disorders such as the Cervella Cranial Electrotherapy Stimulator are expected to aid the market development.
North America to Account for a Significant Share in the Anxiety and Depression Treatment Market
The increasing prevalence of anxiety and depression disorders in the North American countries is leading to the market expansion. According to reports by the United States Center for Disease Control and Prevention, the number of adults with symptoms of anxiety or depression in the region has been increasing. In addition, there is a rise in approval of antidepressant drugs by the governmental organisations in the region, which is resulting in the market development.
Market Segmentation
Anxiety and depression are mental conditions that interfere with daily living. Anxiety is a feeling of excessive apprehension, fear, and worries about everyday situations. On the other hand, depression involves lowering one’s mood and negatively affects how a person thinks or acts. It is necessary to seek medical care and treatments in such conditions.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The anxiety and depression treatment market, by product, is divided into:
- Antidepressant Drugs
- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
- Tricyclic Antidepressants (TCAs)
- Monoamine Oxidase inhibitors (MAOIs)
- Atypical Antipsychotics
- Benzodiazepines
- Anticonvulsants
- Beta-Blockers
- Others
- Therapy and Devices
- Fisher-Wallace stimulator
- Transcranial Magnetic Stimulation (TMS)
- Deep Brain Stimulation (DBS)
- Vagus nerve stimulation (VNS)
- Electroconvulsive Therapy (ECT)
- Cognitive Behaviour Therapy (CBT)
- Others
Based on indication, the market is segmented into:
- Major Depressive Disorder (MDD)
- Obsessive-Compulsive Disorder (OCD)
- Phobia
- Others
The major regions in the market are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
Increasing Cases of Anxiety and Depression, Developing Healthcare Infrastructure, Favourable Government Initiatives, and Drug Developments to Drive the Anxiety and Depression Treatment Market Growth
The increasing diagnosis owing to the developing healthcare infrastructure and the awareness among the population about the importance of the treatment and its efficiency is leading to the incremental market development of anxiety and depression treatment.
The COVID-19 pandemic bolstered the demand for anxiety and depression treatment as many people faced anxiety and depression disorders due to the prolonged confinement to their own houses and lowered social interactions.
In addition, the government initiatives for promoting mental health and preventing mental disorders are aiding the market growth of anxiety and depression treatment. In April 2021, the Government of India launched Mental Health and Normalcy Augmentation System to enhance the mental well-being of Indians.
Further, the innovative developments in the production of antidepressants by the leading market players to escalate their market potential are estimated to augment the market for anxiety and depression treatment.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Key Players in the Global Anxiety and Depression Treatment Market
The report gives an in-depth analysis of the key players in the market, covering their competitive landscape and latest developments like mergers, acquisitions, and investments, and plant turnarounds:
- Pfizer
- GlaxoSmithKline
- Merck and Co. Inc
- AstraZeneca
- Eli Lily and Co.Johnson and Johnson
- Forest Laboratories, Inc
- Sanofi-Aventis
- Others
The comprehensive EMR report offers an extensive assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Product |
|
| Breakup by Indication |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Anxiety and Depression Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Anxiety and Depression Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Anxiety and Depression Epidemiology (2016-2031)
5.3 Europe Anxiety and Depression Epidemiology (2016-2031)
5.4 Asia-Pacific Anxiety and Depression Epidemiology (2016-2031)
5.5 Latin America Anxiety and Depression Epidemiology (2016-2031)
5.6 Middle East & Africa Anxiety and Depression Epidemiology (2016-2031)
6 Global Anxiety and Depression Treatment Market Overview
6.1 Global Anxiety and Depression Treatment Market Historical Value (2017-2023)
6.2 Global Anxiety and Depression Treatment Market Forecast Value (2024-2032)
7 Global Anxiety and Depression Treatment Market Landscape
7.1 Anxiety and Depression Treatment: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Anxiety and Depression Treatment: Product Landscape
7.2.1 Analysis by Product
7.2.2 Analysis by Indication
7.2.3 Analysis by Distribution Channel
8 Anxiety and Depression Treatment Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Anxiety and Depression Treatment Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Anxiety and Depression Treatment Market Segmentation
11.1 Global Anxiety and Depression Treatment Market by Product
11.1.1 Market Overview
11.1.2 Antidepressant Drugs
11.1.2.1 Selective Serotonin Reuptake Inhibitors (SSRIs)
11.1.2.2 Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
11.1.2.3 Tricyclic Antidepressants (TCAs)
11.1.2.4 Monoamine Oxidase inhibitors (MAOIs)
11.1.2.5 Atypical Antipsychotics
11.1.2.6 Benzodiazepines
11.1.2.7 Anticonvulsants
11.1.2.8 Beta-Blockers
11.1.2.9 Others.
11.1.3 Therapy and Devices
11.1.3.1 Fisher-Wallace stimulator
11.1.3.2 Transcranial Magnetic Stimulation (TMS)
11.1.3.3 Deep Brain Stimulation (DBS)
11.1.3.4 Vagus nerve stimulation (VNS)
11.1.3.5 Electroconvulsive Therapy (ECT)
11.1.3.6 Cognitive Behaviour Therapy (CBT)
11.1.3.7 Others
11.2 Global Anxiety and Depression Treatment Market by Indication
11.2.1 Market Overview
11.2.2 Major Depressive Disorder (MDD)
11.2.3 Obsessive-Compulsive Disorder (OCD)
11.2.4 Phobia
11.2.5 Others
11.3 Global Anxiety and Depression Treatment Market by Distribution Channel
11.3.1 Market Overview
11.3.2 Hospital Pharmacy
11.3.3 Retail Pharmacy
11.3.4 Online Channels
11.3.5 Others
11.4 Global Anxiety and Depression Treatment Market by Region
11.4.1 Market Overview
11.4.2 North America
11.4.3 Europe
11.4.4 Asia Pacific
11.4.5 Latin America
11.4.6 Middle East and Africa
12 North America Anxiety and Depression Treatment Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Anxiety and Depression Treatment Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Anxiety and Depression Treatment Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Anxiety and Depression Treatment Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Anxiety and Depression Treatment Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 Pfizer Inc.
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 GlaxoSmithKline plc
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Merck and Co. Inc
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 Astrazeneca
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 Eli Lily and Co.
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 Forest Laboratories, Inc
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 Sanofi-Aventis
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Johnson & Johnson Services Inc.
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Abbvie
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 Merck & Co. Inc.
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
24 Anxiety and Depression Treatment - Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The global anxiety and depression treatment market reached a value of USD 10.05 billion in 2023.
The market is projected to grow at a CAGR of 2.6% during the forecast period of 2024-2032 to reach a value of USD 12.67 billion by 2032.
The market drivers are developing healthcare market, increasing diagnosis of mental conditions, awareness about the importance of treatments, and the rising inclination towards therapies.
The different signs and symptoms of anxiety are increased nervousness or restlessness, hyperventilation, increased heart rate, fatigue, and difficulty to focus or concentrate, among others.
Selective serotonin reuptake inhibitors offer a wide therapeutic range and is used to treat anxiety disorders and depression at the same time.
The key market trends include the growing cases of anxiety and depression disorders, government initiatives to promote the mental health, and the development of antidepressant drugs by leading market players.
The various products considered in the report are antidepressant drugs, therapy, and devices.
The different market divisions, based on indication, include major depressive disorder (MDD), obsessive-compulsive disorder (OCD), and phobia, among others.
The players in the anxiety and depression treatment market are the Pfizer, GlaxoSmithKline, Merck and Co. Inc, AstraZeneca, Eli Lily and Co., Johnson and Johnson, Forest Laboratories, Inc, and Sanofi-Aventis, among others.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER